Pharmacophore an International Research Journal
T2DM (Type 2 Diabetes Mellitus) remains a main global health issue, particularly if cardiovascular complications started to evolve. Type 2 diabetes is the main cause of renal and cardiovascular adverse consequences. Adequate management of T2DM depends on glycemic control and prevent cardiovascular or renal complications. Hence, certain antidiabetic agents have provided cardiovascular protection, of which one of them is the glucose-like peptide 1 receptor agonists. The present literature review aims to assess the cardiovascular efficiency and safety of glucose-like peptide 1 receptor agonists in patients with T2DM. We used the PubMed database, searching for relevant articles to the title. We used the following Mesh words: heart failure, GLP-1 receptor agonist, type 2 diabetes mellitus, cardiovascular consequences. GLP-1 receptor agonists are effective antidiabetic agents in regards to the glycemic control and safety profile for cardiovascular disease. GLP-1 receptor agonists seem to have promising cardiovascular protection in cardiovascular and all-cause mortality, including fatal and non-fatal myocardial infarction, fatal and non-fatal stroke. However, the increased risk of heart failure hospitalization remains debatable, and further clinical trials are recommended to evaluate this concern. A common side effect is related to gastrointestinal upset, and overall, it is transient and generally does not require discontinuation of the treatment.
